Psychedelics Today

In this episode, Kyle interviews Juan Pablo Cappello: co-founder and former CEO of Nue Life Health, whose assets were subsequently acquired by Beckley Waves. Cappello discusses the current challenges and controversies facing a ketamine industry that has moved much faster than anyone anticipated, and stresses the need to create industry-wide standards – especially for at-home ketamine – before the government imposes its own standards on us. Citing the Matthew Perry case and other bad behavior from providers, he talks about the risks of overpromising and underdelivering, the lack of integration in the majority of at-home ketamine frameworks, and how profit-driven, subscription model motives have overshadowed patient care and ethical practices. He also discusses: The complications from personal perspectives and passions shifting after a psychedelic experience, and how that can change over time The FDA’s recent rejection of MDMA: What would have happened to MDMA if it had been approved? Hope for more Native Amer